BC
IRLA

Burleson & Co’s IRulya Therapeutics Inc. Common Stock IRLA Stock Holding History

Burleson & Co’s Portfolio IRLA Stock Details IRLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-454
Closed -$283K – 392
2021
Q3 		$283K Buy
+454
New +$7.22M 0.04% 117

Other funds holding IRLA

ECG
EPIQ Capital Group San Francisco, California $383M AUM 46.87% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Alphabet Inc
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Burleson & Co's IRLA Position: Q4 2022 in Review

Burleson & Co reduced its IRulya Therapeutics Inc. Common Stock (IRLA) stake by 97% in Q4 2022, selling an estimated $247K and leaving 42 shares worth $5.36K. The position accounts for ﹤0.01% of the portfolio, ranked #302.

Burleson & Co first reported a position in IRLA in Q4 2019 and has held it in 13 quarters since. The position peaked at $12.4M in Q3 2021. 48 funds tracked by Wall St. Rank hold IRLA as of Q4 2022.

  • Burleson & Co held 42 shares of IRulya Therapeutics Inc. Common Stock worth $5.36K as of Q4 2022.
  • Burleson & Co sold 1,478 IRulya Therapeutics Inc. Common Stock shares in Q4 2022, an estimated $247K.
  • IRulya Therapeutics Inc. Common Stock made up ﹤0.01% of Burleson & Co's portfolio in Q4 2022, its #302 holding.
  • Burleson & Co first reported a position in IRulya Therapeutics Inc. Common Stock in Q4 2019 and has held it in 13 quarters since.
  • Burleson & Co's IRulya Therapeutics Inc. Common Stock position peaked at $12.4M in Q3 2021.
  • 48 funds tracked by Wall St. Rank held IRulya Therapeutics Inc. Common Stock as of Q4 2022.

Based on Burleson & Co's 13F filing for Q4 2022, filed 31 Jan 2023.